Biomarin Pharmaceutical Company Profile

Aggregated data from the web about Biomarin Pharmaceutical

Company Name	Biomarin Pharmaceutical
Website	https://www.biomarin.com
Snippet	BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes.
Type	Public
Founded	1997
Revenue	US$1.31 billion (2017)
Website	biomarin.com
Founders	Christopher Starr, Ph.D., Grant W. Denison Jr.
Industry	Biotechnology
Products	Kuvan, Naglazyme, Aldurazyme, Firdapse, Vimizim, Brineura, Palynziq
Traded as	Nasdaq: BMRN, Russell 1000 component
Key people	Jean-Jacques Bienaimé, (Chairman & CEO), Daniel Spiegelman, (Executive VP & CFO), Brian R. Mueller, (Senior VP, Finance & CAO)
Net income	US$−117.04 million (2017)
Headquarters	San Rafael, California, U.S.
Total assets	US$4.63 billion (2017)
Total equity	US$2.81 billion (2017)
Operating income	US$−14.7 million (2017)
Number of employees	2,581 (2017)

Biomarin Pharmaceutical is part of the United States company list

Biomarin Pharmaceutical is part of the Biotechnology company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.